Watson Hit With False Marking Suit Over Androderm

Law360, New York (August 17, 2010, 4:18 PM EDT) -- Watson Pharmaceuticals Inc. has been accused of listing expired patents for its Androderm testosterone deficiency treatment, as well as blocking innovation in the industry.

Texas-based Promote Innovation LLC filed suit Monday in the U.S. District Court for the Eastern District of Texas, arguing that Watson has been marking Androderm products with four expired patents: U.S. Patent Numbers 4,849,224; 4,855,294; 4,863,970; and 4,983,395.

According to the qui tam complaint, the '224 patent expired no later than November 2007, the '294 patent expired no later than September 2008,...
To view the full article, register now.